CIMETIDINE TABLET 200mg

Product Information

Registration Status: Active

CIMETIDINE TABLET 200mg is approved to be sold in Singapore with effective from 1997-05-12. It is marketed by NAINA MOHAMED & SONS PTE LTD, with the registration number of SIN09571P.

This product contains Cimetidine 200mg in the form of TABLET. It is approved for ORAL use.

This product is manufactured by MICRO LABS LTD in INDIA.

It is a has been granted the exemption for supply without a presciption if it met certain criteria.

Reclassified Info

Cimetidine

Description

A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. [PubChem]

Indication

For the treatment and the management of acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.

Mechanism of Action

Cimetidine binds to an H2-receptor located on the basolateral membrane of the gastric parietal cell, blocking histamine effects. This competitive inhibition results in reduced gastric acid secretion and a reduction in gastric volume and acidity.

Pharmacokinetics

Absorption
Rapid 60-70%
Distribution
Metabolism
Hepatic
Elimination

Toxicity

Symptoms of overdose include nausea, vomiting, diarrhea, increased saliva production, difficulty breathing, and a fast heartbeat.

Active Ingredient/Synonyms

1-Cyano-2-methyl-3-(2-(((5-methyl-4-imidazolyl)methyl)thio)ethyl)guanidine | 2-Cyano-1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)guanidine | Cimetag | Cimetidin | Cimetidina | Cimétidine | Cimetidinum | N-Cyano-n'-methyl-n''-(2-([(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl)ethyl)guanidine | N''-cyano-N-methyl-n'-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine | Tagamet hb 200 | Ulcerfen | Cimetidine |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank